Key points
- Second consecutive year with $100m+ total revenue
- 10 consecutive annual profits
- 9 consecutive annual dividends
- Cash Reserves increased by 12% to A$252m
- Expenses well controlled at $53m
Full summary
Clinuvel Pharmaceuticals Ltd reported its financial results for the year ended 30 June 2026. The company achieved total revenues of A$94 million, a slight decrease of 1% from the previous year. Despite this, the company maintained a disciplined and balanced approach, with expenses well controlled at A$53 million, resulting in a net profit before income tax of A$48 million, down 8%. Net profit after income tax stood at A$34 million, a decrease of 6%. The company's cash reserves increased by 12% to A$252 million, providing a strong balance sheet. Clinuvel also highlighted its commitment to research and development, with 34% of total expenses allocated to R&D. The company continues to focus on expanding its product range and clinical programs, with several key milestones and product developments planned for the coming years.
Guidance
FY2026 total revenues A$94m, net profit A$34m, cash reserves A$252m
Outlook
Clinuvel plans to expand its American presence, with a focus on treating patients in need and increasing investor interest. The company is also advancing its RD&I efforts and managing its capital discipline.